568 related articles for article (PubMed ID: 19092849)
21. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
[TBL] [Abstract][Full Text] [Related]
22. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.
Paiva C; Rowland TA; Sreekantham B; Godbersen C; Best SR; Kaur P; Loriaux MM; Spurgeon SEF; Danilova OV; Danilov AV
Haematologica; 2017 Nov; 102(11):1890-1900. PubMed ID: 28838991
[TBL] [Abstract][Full Text] [Related]
23. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
24. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
[TBL] [Abstract][Full Text] [Related]
25. Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia.
Kawauchi K; Ogasawara T; Yasuyama M
Int J Hematol; 2002 Jun; 75(5):508-13. PubMed ID: 12095152
[TBL] [Abstract][Full Text] [Related]
26. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Spurgeon SE; Coffey G; Fletcher LB; Burke R; Tyner JW; Druker BJ; Betz A; DeGuzman F; Pak Y; Baker D; Pandey A; Hollenbach SJ; Sinha U; Loriaux MM
J Pharmacol Exp Ther; 2013 Feb; 344(2):378-87. PubMed ID: 23220742
[TBL] [Abstract][Full Text] [Related]
27. The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.
Colado A; Almejún MB; Podaza E; Risnik D; Stanganelli C; Elías EE; Dos Santos P; Slavutsky I; Fernández Grecco H; Cabrejo M; Bezares RF; Giordano M; Gamberale R; Borge M
Cancer Immunol Immunother; 2017 Apr; 66(4):461-473. PubMed ID: 28011996
[TBL] [Abstract][Full Text] [Related]
28. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
[TBL] [Abstract][Full Text] [Related]
29. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells.
López-Guerra M; Xargay-Torrent S; Pérez-Galán P; Saborit-Villarroya I; Rosich L; Villamor N; Aymerich M; Roué G; Campo E; Montserrat E; Colomer D
Leukemia; 2012 Jun; 26(6):1429-32. PubMed ID: 22182921
[No Abstract] [Full Text] [Related]
31. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
Hill RJ; Lou Y; Tan SL
Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
33. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
[TBL] [Abstract][Full Text] [Related]
34. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.
Cha HS; Boyle DL; Inoue T; Schoot R; Tak PP; Pine P; Firestein GS
J Pharmacol Exp Ther; 2006 May; 317(2):571-8. PubMed ID: 16452391
[TBL] [Abstract][Full Text] [Related]
35. Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL.
Shukla A; Rai K; Shukla V; Chaturvedi NK; Bociek RG; Pirruccello SJ; Band H; Lu R; Joshi SS
Blood; 2016 May; 127(19):2310-21. PubMed ID: 26809508
[TBL] [Abstract][Full Text] [Related]
36. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
Yeomans A; Thirdborough SM; Valle-Argos B; Linley A; Krysov S; Hidalgo MS; Leonard E; Ishfaq M; Wagner SD; Willis AE; Steele AJ; Stevenson FK; Forconi F; Coldwell MJ; Packham G
Blood; 2016 Jan; 127(4):449-57. PubMed ID: 26491071
[TBL] [Abstract][Full Text] [Related]
37. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.
Yaktapour N; Meiss F; Mastroianni J; Zenz T; Andrlova H; Mathew NR; Claus R; Hutter B; Fröhling S; Brors B; Pfeifer D; Pantic M; Bartsch I; Spehl TS; Meyer PT; Duyster J; Zirlik K; Brummer T; Zeiser R
J Clin Invest; 2014 Nov; 124(11):5074-84. PubMed ID: 25329694
[TBL] [Abstract][Full Text] [Related]
38. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
[No Abstract] [Full Text] [Related]
39. Reduced expression of the tumor suppressor PHLPP1 enhances the antiapoptotic B-cell receptor signal in chronic lymphocytic leukemia B-cells.
Suljagic M; Laurenti L; Tarnani M; Alam M; Malek SN; Efremov DG
Leukemia; 2010 Dec; 24(12):2063-71. PubMed ID: 20861921
[TBL] [Abstract][Full Text] [Related]
40. Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.
Thomas A; Pepper C; Hoy T; Bentley P
Leuk Lymphoma; 2004 May; 45(5):997-1008. PubMed ID: 15291360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]